This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Mylan Pharmaceuticals Inc.
Mylan Pharmaceuticals Inc., a prominent player in the global pharmaceutical industry, is headquartered in the United States. Founded in 1961, Mylan has established itself as a leader in generic and specialty medications, focusing on improving access to high-quality healthcare. With a strong operational presence across North America, Europe, and Asia, the company has made significant strides in expanding its product portfolio. Mylan is renowned for its extensive range of generic drugs, biosimilars, and over-the-counter products, which are distinguished by their affordability and accessibility. The company has achieved notable milestones, including the launch of the first generic version of the EpiPen, solidifying its market position. Mylan's commitment to innovation and quality has earned it a reputation as a trusted provider in the pharmaceutical sector, making it a key player in enhancing global health outcomes.
DitchCarbon Score
How does Mylan Pharmaceuticals Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mylan Pharmaceuticals Inc.'s score of 45 is higher than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Mylan Pharmaceuticals Inc., headquartered in the US, currently does not have specific carbon emissions data available for recent years. The company is a current subsidiary of Viatris Inc., which may influence its climate commitments and emissions reporting. As part of its corporate family relationship, Mylan's climate initiatives and targets are inherited from Viatris Inc. However, there are no documented reduction targets or significant climate pledges reported for Mylan Pharmaceuticals Inc. at this time. The absence of specific emissions data and reduction initiatives highlights a potential area for improvement in transparency and accountability regarding climate impact. As the pharmaceutical industry increasingly focuses on sustainability, Mylan Pharmaceuticals Inc. may benefit from establishing clear emissions reduction targets and reporting frameworks to align with industry standards.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 302,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 354,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Mylan Pharmaceuticals Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
